Corvus Pharmaceuticals, Inc. (CRVS) Financials
CRVS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 45.6 million | 6.9 million |
2023-09-30 | 51.9 million | 7.7 million |
2023-06-30 | 58.0 million | 8.6 million |
2023-03-31 | 58.2 million | 9.3 million |
CRVS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -5.2 million | 572000 |
2023-09-30 | -5.4 million | 546000 |
2023-06-30 | -5.2 million | 537000 |
2023-03-31 | -8.1 million | 492000 |
CRVS Net Income
No data available :(
CRVS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | - | - | 1.4 million |
2023-09-30 | 32.2 million | - | 1.7 million |
2023-06-30 | 37.0 million | - | 2.0 million |
2023-03-31 | 34.5 million | - | 2.3 million |
CRVS Shares Outstanding
CRVS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 4.0 million | 1.7 million | - |
2023-09-30 | - | 4.0 million | 1.6 million | - |
2023-06-30 | - | 4.0 million | 1.7 million | - |
2023-03-31 | 34000 | 4.6 million | 2.0 million | - |
CRVS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | - |
2023-09-30 | - | 30000 |
2023-06-30 | - | 36000 |
2023-03-31 | - | 57000 |
CRVS
Price: $1.68
52 week price:
Earnings Per Share: -0.56 USD
P/E Ratio: -3.23
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 47000
Ebitda: -12.7 millionMarket Capitalization: 82.4 million